Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639549 | 0.86 | TSHR (0.51) | TSHRGLAALDH1A1KDM4EMAPT | |
| SCHEMBL15651765 | 0.82 | TSHR (0.68) | TSHRALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL2436598 | 0.82 | TSHR (0.55) | TSHRGLAALDH1A1KDM4EMAPT | |
| SCHEMBL8602441 | 0.81 | L3MBTL1 (0.60) | TSHRGLAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2650962 | 0.80 | SMN1; SMN2 (0.65) | TSHRALDH1A1KDM4EMAPTUSP2 | |
| SCHEMBL1805768 | 0.80 | PKM (0.60) | TSHRALDH1A1KDM4EMAPTUSP2 | |
| SCHEMBL23846530 | 0.79 | TSHR (0.50) | TSHRGLAALDH1A1KDM4EMAPT | |
| SCHEMBL15053746 | 0.79 | TSHR (0.69) | TSHRGLAALDH1A1KDM4EMAPT | |
| SCHEMBL1151124 | 0.79 | KDM4E (0.69) | TSHRGLAKDM4EMAPTUSP2 | |
| SCHEMBL31330205 | 0.79 | RAPGEF4 (0.47) | TSHRALDH1A1KDM4EMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022032144-A1 | SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-9051315-B2 | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2496574-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | Abbott Laboratories (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20110124632-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2011053476-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124632-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | PACSIN2, MAP4K2, MAP3K6 | TSHR 3935/4885GLA 3979/4885ALDH1A1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.